Cargando…

Acquiring Pharmaceutical Industry Assets in the UK: 1 + 1 = 1?

The recent AstraZeneca takeover bid from Pfizer puts pharmaceutical R&D once again on the public agenda. Three pertinent questions are (a) what can be expected from this acquisition, (b) what are the implications for the UK economy and science base, and (c) whether such a deal should go ahead. A...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanavos, Panos, Angelis, Aris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4203995/
https://www.ncbi.nlm.nih.gov/pubmed/25346596
http://dx.doi.org/10.1007/s40290-014-0066-2